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Fluticasone propionate (FP) is a novel androstane glucocorticoid with potent anti-inflammatory activity 
which has been effectively used, intranasally, as therapy for seasonal and allergic perennial rhinitis. When 
taken by the inhaled route, FP has shown significant therapeutic efficacy in the management of asthma. 
Fluticasone propionate is a highly lipophilic molecule with good uptake, binding and retention characteristics 
in human lung tissue. Fluticasone propionate has high glucocorticoid receptor selectivity and affinity, 
demonstrating rapid receptor association and slow receptor dissociation. In vitro, FP has been shown to 
potently inhibit T lymphocyte proliferation, cytokine generation, tumour necrosis factor alpha (TNF-CL)- 
induced adhesion molecule expression, interleukin-5-induced eosinophilia, mucosal oedema and toluene 
2,4-diisocyanate-induced mast cell proliferation, while promoting secretory leucocyte protease inhibitor 
production and eosinophil apoptosis. In human studies, FP has demonstrated marked vasoconstrictor 
potency in normal subjects and inhibited antigen-induced mucosal platelet activating factodeicosanoid 
production, T lymphocytes and CD25+ cells in patients with rhinitis. Biopsy data from mild asthmatics 
demonstrate FP-associated reduction in CD3, CD4, CD8 and CD25 cells, with an accompanying reduction in 
eosinophil and mast cell markers. Clinical studies have evaluated lung function, bronchial reactivity, 
exacerbation rates and oral corticosteroid-sparing effect. Results show that FP has at least twice the clinical 
potency of beclomethasone dipropionate and budesonide. This appears to be achieved without an accompa- 
nying increase in systemic effects, suggesting a therapeutic index which may be higher than other currently 
available inhaled corticosteroids. 
Introduction 
Fluticasone propionate (FP) is the latest in a range 
of inhaled corticosteroids indicated for the treatment 
of asthma. Evidence from clinical trials suggests that 
it has improved efficacy compared to other currently 
available inhaled corticosteroids, and that this 
heightened therapeutic effect is achieved without 
an accompanying increase in systemic activity. Over- 
all, the data suggests that FP may have a higher 
therapeutic index than other currently available 
inhaled corticosteroids. 
The aim of this review is to provide an update of 
the data from the many preclinical, pharmacokinetic 
and clinical studies which have examined the effects 
of FP in the management of asthma. 
Preclinical Studies 
DEPOT FORMATION AND TISSUE BINDING 
Unlike most other corticosteroids, the structure of 
FP is based on the androstane, rather than the 
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pregnane, corticosteroid nucleus. It is a highly lipo- 
philic molecule (l), a characteristic which has been 
shown to play a major role in dictating the drug’s 
pharmacological profile, particularly with regard to 
lung tissue interaction. For example, FP has a disso- 
lution time in human bronchial fluid of several hours, 
while more hydrophilic corticosteroids, such as 
flunisolide and budesonide have bronchial dissolu- 
tion times of only a few minutes (2). This is relevant 
to both metered dose inhalers and powder delivery 
systems because particulate matter impacts on the 
airway mucosa. lf this particulate matter has a long 
dissolution time, a drug depot can be formed within 
the airway tissue, enabling a sustained duration of 
action, 
High lipophilicity also has important implications 
for the way in which corticosteroids are taken up 
and retained in lung tissue. A clear correlation has 
been observed (Fig. 1) (3) between lipophilicity and 
binding to lung tissue, with the lipophilic compounds 
FP, beclomethasone dipropionate (BDP) and 
beclomethasone-l7-monopropionate (BMP), exhibit- 
ing more rapid and greater binding activity than 
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Fig. 1 Tissue binding of glucocorticoids to human lung tissue. FP, fluticasone propionate; BDP, beclomethasone 
dipropionate; 17-BMP beclomethasone-17-monopropionate. Source: Hiigger et al. (3). 
more hydrophilic compounds such as budesonide, 
flunisolide and hydrocortisone. Fluticasone propi- 
onate had the highest level of lipophilicity among the 
compounds measured by Hiigger and Rohdewald (2) 
and also exhibits the greatest degree of lung tissue 
binding, approximately 4.89 ng mg ~ i. 
In therapeutic use, it is not just the rate and extent 
of uptake that is important, but also how much of the 
drug is subsequently retained in the lungs. This has 
also been studied in vitro by Hiigger and Riihdewald 
(2). In their study, once corticosteroid uptake into 
lung tissue had occurred, the tissue was placed into 
human plasma until equilibration took place. When 
the amount of drug remaining in the lung tissue was 
then determined, FP was found to have an equilib- 
rium retention value of 2.2 ng mg - ‘, while 
flunisolide and budesonide had values of 0.5 and 
l.Ongmg-‘, respectively, further demonstrating the 
potential advantage of high lipophilicity. 
This is also reflected in preliminary data from 
patients undergoing lung resection. Subjects were 
given 1 mg of inhaled FP prior to surgery. Sample 
lung tissue and blood were taken during surgery 
and assayed for FP levels. During a period of 
180-330 min after surgery, the ratio of FP in the 
lung compared to plasma ranged from 78: 1 to 152: 1 
(4). Published data with budesonide using the same 
methodology showed a lung to plasma ratio of 
approximately 9: 1 (5). 
RECEPTOR AFFINITY AND KINETICS 
Having been retained in the lung tissue, a drug has 
to interact with its receptor to exert its pharmaco- 
logical activity. The ability of corticosteroids to 
undergo such interaction can be determined by com- 
petition assays or by study of binding kinetics. Both 
of these methods have shown that FP has a high 
affinity for the human glucocorticoid receptor (2,6,7), 
approximately 20-fold greater than dexamethasone 
(2,7). In addition, FP has been found to have high 
glucocorticoid receptor selectivity (9), with fast 
receptor association and slow receptor dissociation 
(Table 1) (2). 
These receptor kinetics may have implications for 
the biological response of corticosteroids. When a 
corticosteroid molecule enters a cell and interacts 
with its receptor in the cytosol, the resulting complex 
either interacts with transcription factors in the cyto- 
sol or forms a dimer and penetrates the nucleus to 
interact with the target gene. It is thus the receptor 
complex which triggers the biological response to the 
corticosteroid. Therefore, the different corticosteroid- 
receptor association/dissociation rates that have 
been identified, have important implications for 
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Table I Association and dissociation rates for a range of corticosteroids with the human lung 
glucocorticoid receptor 
Association rate constant 
(1 mol - ‘min ‘) 
Dissociation rate constant 
(min - ‘) 
Dexamethasone 
Methylprednisolone 
Triamacinolone acetonide 
Fluticasone propionate 
8.8 x lo5 10.2 x 10W3 
5.5 x lo5 23.6 x 10W3 
4.9 x lo5 3.0 x lop3 
23.9 x lo5 11.6 x 10K4 
Source: Hiigger and Rohdewald (2). 
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Fig. 2 Dose-dependent plateau response of secretory leu- 
cocyte protease inhibitor activity in the presence of a range 
of corticosteroids. Source: Abbinante-Nissen et al. (15). 
corticosteroid differentiation. The rapid association 
and slow dissociation of FP for example, has been 
found to result in a corticosteroid-receptor complex 
with a half-life of 10 h, the longest half-life of any 
corticosteroid evaluated (2), compared with half- 
lives of 7.5 and 5.1 h for BMP and budesonide, 
respectively (2,6). 
Biological activity in vitro 
The anti-inflammatory activity of FP has been 
demonstrated by its effects on a number of inflam- 
matory mediators and markers in vitro. 
Fluticasone propionate has been found to potently 
inhibit anti-CD3-induced proliferation of T cells taken 
from normal volunteers, with a median effective dose 
(EDSo) value of approximately 0.3 nM. This compares 
with values of 0.8, 2.0 and 5.9 nM for budesonide, 
BMP and dexamethasone, respectively (9). 
Table 2 Correlation of receptor affinity and protease 
inhibitor activity for a range of corticosteroids 
Receptor* Protease? 
affinity inhibitor 
(EC,,; ng ml - ‘) (EC,,; nM) 
Hydrocortisone 
Dexamethasone 
Methylprednisolone 
Triamcinolone 
Fluticasone propionate 
4.7 25.0 
0.4 2.0 
1.0 5-o 
0.2 1.0 
0.02 0.1 
*Human glucocorticoid receptor [See Derendorf et al. (7)]; 
?-See Abbinante-Nissen et al. (15). 
Fluticasone propionate also potently inhibits 
phytohaemagglutinin-stimulated proliferation of 
lymphocytes with almost complete inhibition at con- 
centrations of FP as low as lo- lo M (10). The same 
level of inhibition required concentrations of between 
lo- * M and 10 - 6 M for budesonide and BDP. 
Interestingly, in the same study, the proliferation of 
lymphocytes from corticosteroid-resistant patients 
could also be inhibited by FP with approximately 
50% inhibition at 10 ~ lo M. Inhibition was virtually 
complete at 10 - ’ M. Hydrocortisone was virtually 
inactive in the same system while budesonide 
and BDP showed only partial inhibition at high 
concentrations. 
Cytokine generation is inhibited by FP in a range 
of human cells (11-14). In mast cell studies, for 
example, FP was found to have IC,, values of < 1 nM 
for inhibition of interleukin-4 (IL-4), IL-6, IL-8 and 
tumour necrosis factor alpha (TNF-a) (14). In 
contrast, dexamethasone was found to have IC,, 
(inhibitory concentration of a receptor antagonist 
required to inhibit 50% of an agonist response) 
values of approximately 10 nM when assessed against 
the same individual parameters. This is consistent 
with the relative difference in receptor affinity, 
approximately lo-fold in favour of FP (4,7). 
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Table 3(a) Summary of clinical studies of fluticasone propionate vs. beclomethasone dipropionate 
Reference 
Patient 
numbers 
FP 
daily dose 
w 
BDP 
daily dose Treatment 
w duration 
Comparative 
efficacy*/safety P-value 
Dahl et al. (30) ?I=672 100, 200 400 (MDI) 4 weeks 4.31min-’ 
400,800 (MDI) -Morning PEFR increase/daily 
dose P= 0.001 
-Evening PEFR increase/daily 
dose 3 lmin-’ P=O,O17 
Fabbri et al. (31) n=274 1500 (MDI) 1500 (MDI) 12 months 15 (CI 6,25) P<O-005 
-Evening PEFR PiO.05 
-Rescue medication PiO-05 
-Clinic PEFR PCO.05 
-FEV, PCO.05 
-Exacerbation rate PCO.02 
Cortisol P=n.s. 
Leblanc et al. (34) n=261 200 (MDI) 400 (MDI) 4 weeks 4 (CI - 4,12) P=O*368 
-Cortisols P=O.O06 
Lundback et al. (35) n=585 500 (MDI) 1000 (MDI) 6 weeks 4 (CI - 5,14) MD1 P=@361 
6 weeks 500 (DH) 6 (CI - 3,15) DH P=O*214 
n=489 (12 months -Diurnal variation P=O.O3 
12 months safety) Clinic PEFR P=O.O13 
-12 month clinic PEFR P=O,O2 
-12 month clinic FEV, P=O.O25 
-Cortisol P=n.s. 
Bootsma et al. (58) n=281 750 (MDI) 1500 (MDI) 3 weeks Histamine PC,, P=O.O94 
Ultra-nebulized distilled water P=O*926 
FEV, P=O*365 
Barnes et al. (32) n=154 1000 (MDI) 2000 (MDI) 6 weeks 7 (CI - 21,7) P=O*346 
-Diurnal variation P=O.O38 
-Clinic PEFR P=O.O46 
-Cortisols P= 0.026 
Lorentzen and n=235 1000 (MDI) 2000 (MDI) 12 months 3 (CI - 19,24) (Chic PEFR) P= 0.806 
Dahl (36) -FE%‘, 6 months P=O.O4 
-Reversibility 12 months P=O,O44 
Cortisols 6 months P=O.OOS 
-Cortisols 12 months P=O.Ol 
Concentrations required to inhibit epithelial cell 
cytokine production were slightly greater, with IC,, 
values of 5 nM, 10 nM and 1 nM for inhibition of 
IL-6, IL-8 and granulocyte-macrophage colony- 
stimulating factor, respectively. However, FP 
potently inhibited epithelial TNF-a generation, with 
an IC,, value of 0.1 nM. Fluticasone propionate has 
also been shown to inhibit platelet-derived growth 
factor stimulated production of IL-l-p and IL-6 in 
human alveolar macrophage and fibroblast cells. The 
IC,, value was found to be 0.1 nM for inhibition of 
IL-l-p and IL-6, respectively, in both cell types (13). 
In addition to down-regulation of pro-inflammatory 
processes, corticosteroids also appear to exert anti- 
inflammatory activity by increasing endogenous anti- 
inflammatory mechanisms. One such mechanism is 
secretory leucocyte protease inhibitor (SLPI) produc- 
tion. A study evaluating the ability of corticosteroids 
to increase SLPI production in human airway epi- 
thelial cells has demonstrated a clear concentration- 
dependent response (Fig. 2) (15). Potency is again seen 
to correlate with receptor affinity (Table 2) (7,15). 
Fluticasone propionate with the highest receptor affin- 
ity has the lowest EC,, value in this assay compared 
with the other glucocorticoids tested. 
Interestingly, receptor affinity has also been found 
to correlate with the level at which activity reaches a 
plateau; high affinity corticosteroids such as FP have 
a higher plateau of effect than lower affinity cortico- 
steroids such as dexamethasone. This supports the 
emerging concept that corticosteroids may have dif- 
fering levels of pharmacological efficacy. This con- 
cept has been clearly demonstrated for drugs acting 
at membrane receptors, but not as yet for drugs such 
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Table 3(b) Summary of clinical studies of fluticasone propionate vs. budesonide 
Reference 
FP Budesonide 
Patient daily dose daily dose Treatment Comparative 
numbers (1.18) (wd duration efficacyt/safety P-value 
Ayres et al. (37) 
Langdon and 
Thompson (38) 
Langdon and 
Capsey (39) 
n=671 1000 (MDI) 1600 (MDI) 6 weeks 9 (CI 2,17) P=O-018 
2000 (MDI) 13 (CI 6,21) P<O*OOl 
-Evening PEFR (2000 ug 
vs. BUD) P<O.OOl 
-Diurnal variation 
(1000 ug and 2000 ug vs. 
BUD) P=O,O28, P=O.O24 
Clinic PEFR (1000 ug and 
2000 ug vs. BUD) P=O.O41, P=O.O03 
Clinic FEV, (1000 ug and P=O.O15 
2000 ug 1’s. BUD) PCO.01 
-Clinic FVC (2000 ug) P=O.OOl 
-Cortisol (FP2 vs. BUD) PCO.01 
-Cortisol (FPl vs. BUD) P=n.s. 
n= 157 200 (MDI) 400 (MDI) 8 weeks 8 (CI - 15,31) P=O*36 
Cortisol P=n.s. 
n=215 400 (DH) 800 (TH) 8 weeks 20 (CI 5,34) P= 0.009 
-Device preference P=O.O05 
Cortisol P=O,87 
*Primary efficacy variable (Bold text)= Difference (FP minus BDP, or FP minus BUD mean and confidence intervals) in 
morning PEFR unless indicated. Other efficacy variables shown are those for which fluticasone propionate was statistically 
significantly better than BDP or BUD. FP, Auticasone propionate; BDP, beclomethasone dipropionate; BUD, budesonide; 
SCG, sodium cromoglycate; PEFR, peak expiratory flow rate; FEV,, forced expiratory volume in one second; FVC, forced 
vital capacity; MDI,metered dose inhaler; DH, Diskhaler@ t. TH, Turbuhaler@. 
as corticosteroids, which exert their activity via 
intracellular receptor binding. 
A relatively recently recognized property of corti- 
costeroids is the ability to induce eosinophil cell 
death. Fluticasone propionate has been shown to be 
highly potent, with the ability to counter the effects of 
IL-5, an agent which attenuates the effects of 
corticosteroid-induced eosinophil cell death. While 
1 ppm of IL-5 almost completely overcomes the 
effects of 100 nM dexamethasone, marked apoptosis 
is still observed when the same concentration of IL-5 
is used in the presence of 1 nM FP (16). 
Fluticasone propionate has also been studied for 
its effects on adhesion molecule expression. Human 
endothelial cells have been grown in culture and 
stimulated with TNF-a in the presence of increasing 
concentrations of FP (17). Although there is little 
inhibition of ICAM (intercellular adhesion molecule) 
expression, except at very high concentrations, FP 
does differ from earlier corticosteroids (18) in that 
there is a clear concentration-dependent inhibition of 
E-selectin and VCAM (vascular cell adhesion mol- 
ecule) expression. In terms of ED,,, the potency of 
FP is around 20-fold and nine-fold greater than 
dexamethasone and budesonide, respectively. 
In vivo anti-injfammatory activity 
A range of in vivo studies have also demonstrated 
the anti-inflammatory activity of FP. 
Guinea pigs treated with FP, 30 min before 
intratracheal administration of IL-5, have been com- 
pared to untreated and control animals also receiving 
IL-5. Eosinophil numbers in bronchoalveolar lavage 
fluid (BALF) were measured after 24 h. Fluticasone 
propionate was found to have potent inhibitory 
activity against IL-5-induced eosinophilia, with pre- 
treated animals having BALF eosinophil concentra- 
tions similar to those of control animals (19). 
Inhibition of histamine challenge-induced mucosal 
oedema, a model not traditionally recognized as 
being highly corticosteroid responsive, has also been 
investigated (20). There was some inhibition with 
BDP at the earliest time, but this was rapidly lost. In 
contrast, however, FP, at 10% of the dose of BDP, 
gave a marked and longer lasting response. 
In a further study, a 5% toluene diisocyanate 
solution was administered intranasally to rats, over 
an 8-week period, to increase mast cell proliferation 
in rat nasal mucosa. Fluticasone propionate treat- 
ment was found to potently inhibit this response, an 
intranasal dose of 50 ug day- ’ reducing mast cell 
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Fig. 3 Mean change from baseline in peak expiratory flow rate (PEFR) for the same dose of fluticasone propionate (FP) 
and beclomethasone dipropionate (BDP) (1.5 mg day I). Source: Fabbri et al. (31). 
numbers to basal levels (21). The study demonstrates 
the ability of FP to decrease inflammatory cell 
accumulation induced by an intranasal stimulus. 
Human volunteer studies 
A number of ex vivo studies have evaluated the 
biological effects of FP. Two recent studies have used 
the MacKenzie skin vasoconstrictor test to rank the 
anti-inflammatory profile of corticosteroids by evalu- 
ating the blanching effect after topical administration 
(9,22). English et al. (9) found that FP had a vaso- 
constrictor potency at least two- to three-fold greater 
than budesonide and BDP over the linear portion 
of the dose-response curve. In contrast, Andersson 
et al. (22) concluded that FP had comparable effects 
to BUD. However, if only the linear portion of the 
dose-response curve, rather than the entire sigmoid 
curve, was analysed, the results were comparable to 
those of English et al. (9). 
Fluticasone propionate has also been shown to 
inhibit antigen-induced mucosal platelet activating 
factor and eicosanoid production in normal volun- 
teers (23). Additionally, in patients with rhinitis, FP 
has been shown to reduce nasal eosinophil and 
basophil numbers (24), while also inhibiting the pro- 
duction of antigen-induced mucosal T lymphocytes 
and CD25+ cells (25). 
When a 3-month study involving twice-daily admin- 
istration of FP, 1 mg, was carried out in mild asthmat- 
ics, biopsy data showed a marked reduction in CD3, 
CD4, CD8 and CD25 cells, with an accompanying 
reduction of eosinophil and mast cell markers (26). 
Clinical Studies 
While in vitro and in vivo studies may show clear 
dose effects and differences between corticosteroids, 
demonstrating such differences clinically is less 
straightforward. 
MEASURING DOSE-RESPONSE 
Lung function data comprising peak expiratory 
flow rates (PEFR) are currently the standard means 
of measuring the clinical effect of corticosteroids. 
Using such methods, it is difficult to demonstrate 
differences between corticosteroids and, in particular, 
it has been thought that it was not possible to 
demonstrate a clear dose-related response to inhaled 
corticosteroids (ICS). In addition, important sub- 
group responses may be masked. 
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Fig. 4 Differing exacerbation rates for treatment with the 
same dose of fluticasone propionate (FP) and beclometha- 
sane dipropionate (BDP) (1.5 mg day-‘) Source: Fabbri 
et al. (31). 
A recent study has suggested that evaluation of 
bronchial reactivity using challenge with specific or 
non-specific stimuli may have an advantage over lung 
function data in that it can be used to show the 
differences between corticosteroids at low doses. 
Evaluation of rates of asthma exacerbation may also 
have utility for showing differences between low 
doses of inhaled corticosteroids. In the U.S.A., 
placebo-controlled studies with inhaled corticoster- 
oids can be performed, using strict, pre-defined with- 
drawal criteria to remove patients from the study if 
treatment is ineffective. Therefore, it is possible to 
directly compare the rates of exacerbation in patients 
treated with different doses of inhaled corticosteroids 
or with placebo. Chervinsky et al. (27) using this 
method, showed a clear dose-related reduction 
in exacerbations of asthma with FP at doses of 
50ugday-l,200ugday-‘and lOOOugday-‘. 
The capacity of FP to allow reduction or with- 
drawal of oral corticosteroids has also been studied 
(28) and, most recently, preliminary data have been 
generated looking at the ability of FP to treat acute 
exacerbations of asthma (29). 
Low dose-response 
Pulmonary dose-response to low-dose inhaled FP 
has also been demonstrated. A study has compared 
histamine-induced bronchial reactivity in groups of 
25 patients who received placebo, FP, 100 ug, or 
FP, 200 pg. Change in PD,, (provocation dose 
required to produce a 20% reduction in response) 
from baseline was monitored over 8 weeks. By the 
second week, a difference between the higher and 
lower dose was observed. This dose-dependent dif- 
ference was maintained over the whole treatment 
period, the lower dose never becoming significantly 
more than placebo with regard to effect on 
histamine-induced bronchial reactivity. The method, 
therefore, appears to have utility for measuring the 
clinical difference between doses at the lower end of 
the dosage range. 
High dose-response 
Dose-response at the higher end of the dosage 
range has been demonstrated in an oral. prednisone 
sparing study. Patients stabilized on prednisone, 
5-10 mg day- ’ were randomized to receive either 
placebo, FP, 1.5 mg day- ‘, or FP, 2.0 mg day- ‘, for 
16 weeks (28). Prednisone was then reduced by 2.5 mg 
week- ‘. By the end of the study, oral prednisone 
could be completely withdrawn in 88% of patients 
receiving the higher dose of FP and in 69% of patients 
receiving the lower dose. Only 3% of patients in the 
placebo group could discontinue oral corticosteroid 
treatment. Patient withdrawal from the study due to 
exacerbation was higher in the FP, 1.5 mg, than the 
FP, 2.0 mg, group. In spite of the reduction in oral 
corticosteroids, lung function improved significantly 
in both of the FP-treated groups compared with 
placebo. A study performed in the same manner, but 
using budesonide, 0.8 mg and 1.6 mg, failed to show a 
dose-dependent association with prednisone-sparing 
effect or exacerbation rate (59). 
COMPARATIVE STUDIES 
A dose-ranging study by Dahl et al. compared FP 
at daily doses of 100, 200, 400 and 800 ug, with BDP 
at a dose of 400 ug (30). A significant dose-related 
increase in lung function was seen. In addition, 
changes in morning PEFR were found to be similar 
for FP, 200 ug and BDP, 400 ug indicating a 2:l 
efficacy advantage in favour of FP and reflecting the 
potency differences in experimental models. Impor- 
tantly, a dose-related reduction in exacerbations of 
asthma was demonstrated. Based on the experimental 
observations and the results of this study, a number 
of studies were carried out comparing FP with other 
corticosteroids given at twice the dose. A list of the 
clinical studies comparing FP with placebo, BDP and 
budesonide is shown in Tables 3(a) and 3(b). 
In order to demonstrate increased efficacy at com- 
parable doses, a 12-month study by Fabbri et al. (31) 
was carried out comparing FP and BDP at 1.5 mg 
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Fig. 5 Individual plasma cortisol levels at baseline and after 6 weeks treatment with fluticasone propionate and 
beclomethasone dipropriate, respectively. Source: Barnes et al. (32). 
day ~ I. It showed that improvement in morning PEFR 
is significantly greater with FP than with BDP given at 
the same dose (Fig. 3). Importantly, exacerbations, 
particularly severe exacerbations, were also signifi- 
cantly fewer in patients treated with FP compared to 
the same dose of BDP (PcO.02) (Fig. 4) (31). However, 
despite the greater potency of FP, there was no differ- 
ence between treatments in systemic activity deter- 
mined by basal serum cortisol levels and response to 
adrenocorticotropic hormone stimulation. 
A potency advantage for FP over BDP without 
increased systemic activity has also been demon- 
strated in a double-blind, randomized, parallel group 
study by Barnes et al. (32). Fluticasone propionate, 
l.Omgday-‘, was found to be at least as effective as 
BDP, 2.0 mg day- ‘, for control of severe asthma. 
The study monitored individual cortisol levels before 
and after the study period. Scatter plot analysis 
showed that the majority of patients in the 
FP-treated group had either similar cortisol levels 
before and after treatment or had increased levels 
after treatment (Fig. 5). In contrast, a number of 
BDP-treated patients had lower cortisol levels follow- 
ing treatment and the mean values at the end of 
treatment were significantly higher in the FP-treated 
group (P=O.O26). 
A study by Boe et al. (33) set out to evaluate the 
clinical efficacy gained by severe asthmatics from 
increasing the dose of inhaled corticosteroids. The 
paper concluded that there was no difference in 
efficacy between BDP, 1.6 mg, and FP, 2.0 mg. How- 
ever, examination of the study protocol raises a 
number of concerns. 
It can be seen, for example, that one-half of the 
patients had had no incidences of hospitalization due 
to exacerbations and did not meet any of the criteria 
for inclusion in the study. Many of the patients had 
asthma which was much milder than required for 
fulfilment of protocol criteria and the vast majority 
were not on BDP, 1.6 mg day - ‘, or equivalent before 
the study. In fact, one-third of patients received BDP, 
0.8 mg or less. As expected, because of the increase in 
corticosteroid dose, both treatments increased PEFR 
quite markedly. Interestingly, there is still a numeri- 
cal, if not significant, difference in favour of FP in 
spite of the patient population studied and the low 
power of the study to detect a difference. 
A further double-blind study by Ayres et al. has 
compared budesonide, 1.6 mg day- ‘, with FP, 
1.0 mg day-’ and 2.0 mg day- ’ (37). The authors 
proposed that if budesonide had a similar clinical 
potency to FP, then budesonide would produce a 
response that lay between that of the two differing 
doses of FP. In fact, lung function data showed 
budesonide to have less effect than either dose of FP 
(Fig. 6). The magnitude of the changes are such, 
however, that it is difficult to ascertain the extent of 
their clinical relevance. To try and determine this, 
data were analysed in terms of proportion of patients 
showing a 10% change in predicted morning PEFR at 
6 weeks. It can be seen from Fig. 7 that with 
budesonide, 1.6 mg day- ‘, about twice as many 
patients showed an improvement of at least 10% of 
their predicted value than deteriorated by - 10% of 
the predicted value. With FP, 1.0 mg day - i, how- 
ever, three-fold more patients improved by lo%, 
rising to lo-fold for FP, 2.0 mg day - ‘. Interestingly, 
in about 66% of patients, no change in this lung 
function parameter occurred, irrespective of which 
drug or dose they were given. Clearly, if a way could 
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Fig. 6 Relative changes in morning peak expiratory flow rate for 1.6 mg day- ’ budesonide (BUD), 1 mg day ’ 
fluticasone propionate (FPl) (FP2). Source: Ayres et al. (37). 
be found to identify responsive patients clinically, it 
could markedly change clinical studies and clinical 
practice. 
The study also showed dose-dependent decreases 
in morning serum cortisol levels, with budesonide, 
1.6 mg day - ‘, having a suppressive effect between 
that of FP, 1 mg and 2 mg. This lack of increased 
systemic activity with FP, despite its greater clinical 
potency, further supports the assertion that FP has a 
higher therapeutic index than budesonide. 
Treatment of exacerbations 
Inhaled corticosteroids are known to reduce the 
occurrence of asthma exacerbations. However, for 
the treatment of acute exacerbations, oral cortico- 
steroids are generally recommended. A study has been 
performed in the U.K. involving patients presenting 
with acute exacerbations, which, in the opinion of 
their GP, necessitated a course of prednisone but not 
hospitalization (29). This randomized, double-blind 
study compared a reducing course of oral prednisone 
(40 mg daily, reduced by 5 mg every 2 days) with 
inhaled FP, 2 mg day ~ i. Treatment success, defined 
as an improvement in forced expiratory volume in 1 s 
(FEV,) of 2 lo%, was approximately 48% in both 
groups. Time course of improvement and onset of 
action were also very similar for both groups. In both 
groups around 25% of patients had to withdraw 
due to treatment failure. These preliminary results 
suggest that inhaled corticosteroids may be able to 
replace oral corticosteroids in the treatment of acute 
exacerbations of asthma. 
TOLERABILITY 
If the equivalent efficacy of FP at lower doses than 
other inhaled corticosteroids was merely a measure of 
higher potency, then the systemic side-effects of FP 
should also be greater. However, comparative studies 
of FP do not indicate that this is the case. In studies 
comparing FP dose for dose with BDP or budes- 
onide, no significant increase in the suppression of 
plasma cortisol levels was seen with FP compared to 
BDP or BUD (31, 41). While one study claimed to 
show increased suppression of plasma cortisol, in this 
case FP had been administered at a higher dose (42). 
In studies where FP was administered at one- 
half of the dose of BDP, FP was shown to have 
fewer side-effects at doses that gave comparable or 
better efficacy. At high doses of corticosteroids, 
(2.0 mg day- I), a fall in serum cortisol levels of 
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Fig. 7 10% change in predicted morning peak expiratory flow rate at 6 weeks for 1.6 mgday-’ budesonide (BUD), 
1 mg day ’ fluticasone propionate (FP) and 2 mg day - r. Source: Ayres et al. (37). 
approximately 20% has been seen. Fluticasone pro- 
pionate gave similar results to those previously seen 
with both budesonide and BDP (Table 4) (32,37,40). 
Thus, milligram for milligram, FP has a similar effect 
on cortisol levels as do BDP and budesonide. 
PAEXDIATRIC STUDIES 
The clinical efficacy advantage of FP over other 
inhaled corticosteroids has also been demonstrated in 
children (Table 5). In a double-blind, placebo- 
controlled paediatric study, for example, FP, 400 pg 
day ~ ‘, delivered via a Diskhaler was compared with 
budesonide, 400 ug day - ‘, delivered via a Turbu- 
hale@). Morning PEFRs were measured over an 
&week treatment period. Fluticasone propionate was 
found to produce a significantly greater improvement 
than budesonide (43). Overall, 40% of patients on FP 
improved by 10% of predicted PEFR, despite the fact 
that at the beginning of the study the lung function of 
the patients was near normal. Neither drug had a 
marked effect on cortisol values, although there was a 
significant difference in favour of FP. 
A further study in children with mild and moderate 
asthma, has compared FP, 200 ug day - I, with BDP, 
400 pg day- ‘. Results again appear to support the 
efficacy advantage of FP, with morning PEFRs 
significantly greater in the FP-treated group even 
when used at the lower dose (P<O.O5) (44). 
There was no significant difference between treat- 
ments with respect to safety parameters. 
Paediatric safety 
Clinical studies at doses of FP, up to 400 ug 
day- r, support the safety profile of FP in children 
(Table 5). For example, one study (45) has compared 
FP, 100 ug day- ‘, with sodium cromoglycate, 
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Table 4 Published studies: effects of high doses of corticosteroids on plasma cortisol levels 
Changes in mean morning cortisol levels 
Reference Treatment 
Ratio 
(pre:post) 
Ayres et al. (37) 
Barnes et al. (32) 
Toogood et al. (40) 
Fluticasone propionate 2.0 mg 
Beclomethasone dipropionate 2.0 mg 
Budesonide 2.0 mg 
0.88 
0.875 
0.82 
Table 5 Summary of clinical studies of fluticasone propionate in children 
Reference 
FP dose Comparator Treatment Comparative 
(ug day i) daily dose (ug) duration efficacy/safety P-value 
Gustafsson et al. (44) 
n=398 
Paediatric 
200 (MDI) BDP 400 
WW 
Hoekx and Hollingworth (43) 400 (DH) BUD 400 
?I=229 CW 
Paediatric 
Price and Weller (45) 
n=225 
100 (DH) SCG 80 mg 
Wolthers and Pedersen (48) 
n=19 
Agertoft and Pedersen (49) 
n=2 x 24* 
200 (DH) BDP 400, 
800 (DH) 
200 (DH) BUD 200 
400 (DH) (TH) 
BUD 400 
UH) 
6 weeks 1.7 (CILO.1, 3.5) 
(NB. Percentage 
predicted PEFR) 
-Morning PEFR 
(weeks 3, 6) 
-Evening PEFR 
-Days with no exercise 
symptoms 
-Rescue-free days 
-Use of rescue 
-Cortisol 
8 weeks 3 (CI 1,5)(percentage 
predicted PEFR) 
7 (CI 1,14) 
(absolute PEFR) 
-Evening PEFR) 
(percentage predicted) 
-Cortisol (weeks 4, 8) 
8 weeks Percentage predicted PEFR 
symptom-free days/nights 
AE FP<SCG 
2 weeks Knemometry 
VS. BDP 400 ug 
VS. BDP 800 ug 
2 weeks Knemometry 
200 ug VS. 200 ug BUD 
400 ug V,S. 400 ug BUD 
Urinary cortisol/creatinine 
200 ug VS. 200 ug BUD 
400 1.18 VS. 400 ug BUD 
P=O.O69 
P=O.O44 
P=O.O43 
P=O.O41 
P=O.O4 
P=O.O46 
P=O.O44 
P=O,989 
P=O.O07 
P=O.O19 
P=O.O17 
P=O.O2, 0.07 
P<O.OOl 
PCO.05 
P=O.O03 
P<O.OOl 
P=O.19 
P=O.39 
P=O.O7 
P=O,29 
*Each group treated at one dose level. See Table 3 for abbreviations. 
20 mg, taken four times a day. While the efficacy 
difference in favour of FP was unsurprising, it was 
interesting to note that the incidence of withdrawals 
due to adverse events was greater in the cromoglycate 
group. 
The effect of inhaled corticosteroid therapy on 
paediatric growth has been one area of particular 
concern. Height data have been recorded in 41 chil- 
dren (25 males, 16 females) aged 6-12.4 years treated 
with FP, 100-200 pg day - ’ for a mean of 1.2 yr (46). 
Height velocity standard deviation scores were calcu- 
lated for all patients. Growth during treatment was 
not significantly different from national standards 
(47). Although more studies are required, these data 
appear to support other observations that FP has a 
negligible effect on growth. 
Separate studies have compared FP with BDP, 
and FP with budesonide using the technique of 
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knemometry. This technique, which accurately mea- 
sures short-term changes in lower leg length, is 
apparently of little value for predicting final height, 
but is a very sensitive measure of systemic exposure. 
Fluticasone propionate, at 200 ug day - *, com- 
pared with BDP, 400 ug day ~ ’ and 800 pg day- ‘, 
had less of an effect on lower leg growth (48). In a 
separate placebo-controlled comparison with budes- 
onide, FP was shown to have comparable effects at 
the same daily dose: FP, 200 ug, vs. budesonide, 
200 ug; and FP, 400 ug, vs. budesonide, 400 ug (49). 
PHARMACOKINETICS 
Experimental and clinical data clearly show that 
FP is more effective than other currently available 
inhaled corticosteroids, dose-for-dose. However, 
there does not appear to be a concomitant increase in 
systemic effects. This may be explained by the 
absorption characteristics and metabolic profile of 
the drug. 
After intravenous dosing, FP displays a three- 
phase kinetic profile. At doses over the range 0.25- 
1.0 mg, there was no evidence of saturation of 
metabolism as the plasma profiles when normalized 
for dose were superimposed. Fluticasone propionate 
is extensively distributed in the body (volume of 
distribution is 318 1) and it is rapidly cleared 
(1.11 1 min - ‘). The terminal elimination half-life is 
7.8 h, largely due to the third phase of the profile 
which is likely to represent re-equilibration from the 
tissues (50). 
Metabolism of FP is by de-esterification in the 
liver. There is no evidence of any saturation of this 
process at intravenous doses up to 4 mg (51). In 
addition, the frequency distribution of clearance 
values shows that there is no evidence of genetic 
polymorphism of the metabolism of FP in the 
populations studied. Fluticasone propionate is a 
single enantiomer and, therefore, it is not necessary 
to take into account possible differences between 
enantiomers as is the case for racemic mixtures, such 
as budesonide. 
When considering the pharmacokinetic be- 
haviour of a drug after inhaled dosing, it is neces- 
sary to take into account a number of additional 
factors: the rate of absorption and the fate of the 
proportions of the dose which reach (1) the gut, and 
(2) the lungs. 
The kinetic parameters of FP, in particular the 
high clearance rate which approaches that of liver 
blood flow, predict that any swallowed drug will be 
deactivated almost completely on first pass through 
the liver. This has been confirmed in a study compar- 
ing FP after intravenous (0.25 mg single dose) and 
oral (0.1 mg, 1 mg and 10 mg twice daily) dosing 
over 3.5 days. The systemic availability of the oral 
doses was confirmed at less than 1% compared 
with approximately 11% for budesonide, 10% for 
triamcinolone and 20% for flunisolide. 
A study in mild asthmatic patients compared oral 
FP, 20 mg day - ‘, for up to 4 weeks with inhaled FP, 
0.5 mg b.d. Plasma levels of FP were the same order 
in spite of the difference in dose (area under curve 
1.4 ng h ml ~ ’ after oral dosing, 05 ng h ml - ’ after 
inhaled dosing). However, the oral dose was com- 
pletely ineffective in improving FEV, and was no 
different from placebo, whereas inhaled FP improved 
lung function significantly compared with both oral 
FP and placebo, thus confirming the topical activity 
of FP (52). 
There are a number of factors which determine the 
systemic activity of a corticosteroid after inhaled 
(and also intranasal) dosing: (1) rate of absorption 
through the lung (or nasal) mucosa; (2) dosage 
interval and (3) deposition of drug at the target 
organ. 
(1) The concentration-time profile after inhaled 
dosing with FP is quite different from the intravenous 
profile. There is a slow appearance of drug in the 
plasma due to dissolution of drug at the mucosal 
surface followed by rapid uptake into the tissue 
because of the high lipophilicity of the molecule. This 
property also means that the drug is preferentially 
retained in the tissue and is released slowly into the 
plasma. This rate of absorption is slower than the 
elimination/clearance and, therefore, there is a pro- 
longation of apparent half-life relative to that seen 
after intravenous dosing, with values of around 10 h 
(range 7-14 h). 
As for intravenous dosing, the kinetic profiles 
after inhaled dosing are superimposable over a range 
of doses (0.5-2.0 mg) showing that there is no satu- 
ration of the kinetics of FP with this route of 
administration. 
Taking into account the variability of deposition of 
drug in the lung, absolute bioavailability after 
inhaled dosing has been estimated at approximately 
20% of the total delivered dose. 
With intranasal dosing, plasma levels of FP were 
undetectable in a large proportion of cases, making 
it impossible to accurately determine pharmaco- 
kinetic parameters. The maximum possible bio- 
availability has been estimated at less than 2% 
using the limited samples where blood levels were 
detectable, and therefore this is likely to be an 
overestimate (53). This contrasts with published 
levels for budesonide of approximately 102% (54) 
and flunisolide of 49% (55). 
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Fig, 8 Cortisol levels over a 3-day period showing an asymmetrical daytime/night-time distribution. Source: Rohatagi 
et al. (57). 
(2) Inhaled FP has been given to volunteers repeat- 
edly every 12 h for periods of 7 days with a maximum 
of 1 .Cfold accumulation. 
(3) A consistent observation throughout the large 
clinical pharmacology programme is that there is a 
large inter-patient variability of FP (approximately 
lo-fold) in blood levels after inhaled dosing, irrespec- 
tive of the delivery system used. Measurements 
within any individual patient appeared to be more 
consistent. This appears to be a function of the 
deposition of drug in the lung and the ability of 
the patient to use the delivery system optimally, 
which strongly supports patient individualization of 
delivery system. 
Thus, the chemical properties of FP, including low 
aqueous solubility and metabolic activation in vivo, 
result in slow absorption into the circulation after 
inhaled dosing, and rapid clearance from the body. 
Any swallowed dose is removed by almost complete 
first-pass metabolic inactivation. Drug levels at the 
site of action in the lung are maximized, which 
explains the observed separation of clinical and 
systemic potency. 
Pharmacokinetic and Pharmacodynamic Modelling 
The development of mathematical models, which 
allow the prediction of systemic pharmacodynamic 
effects from corresponding pharmacokinetic param- 
eters and vice versa, will provide us with additional 
information on the comparative systemic effects of 
inhaled corticosteroids. 
Such models, originally developed by Holford and 
Sheiner (56), have been used to study the effects of FP 
on serum cortisol levels. Traditional measures of 
cortisol suppression are notoriously imprecise as 
cortisol levels fluctuate naturally throughout the 
course of the day. However, modelling techniques 
have been able to provide a mathematical link 
between the FP concentrations in the plasma and 
serum cortisol levels which is independent of time, 
dose, formulation and delivery route. 
The models were used to relate the plasma levels of 
FP, after a single dose of FP, with the corresponding 
changes in serum cortisol levels (compared to placebo 
values) over a 12-h period from 10 a.m. to 10 p.m. 
These two sets of values, after computer manipula- 
tion using the HolfordBheiner approach, give an 
EC,, value for FP’s effects on serum cortisol. This, 
and the other model parameters, can be used to 
predict the systemic effects from any FP plasma level 
profile. 
The predictive value of the model was validated 
using results from a study of a single dose of FP 
administered via a dry powder device to healthy 
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male volunteers in which FP of two different bio- 
availabilities was used (Glaxo data on file). All 
other pharmacokinetic parameters were identical. 
The data provided by the study results of the 50% 
bioavailable formulation of FP were used to 
construct a model that gave an accurate prediction 
of serum cortisol effect for the 100% bioavailable 
FP. 
The validity of the pharmacokinetic/pharmaco- 
dynamic model has also been proved over a 24-h 
period following research which indicated that corti- 
sol levels during the night follow a widely different 
pattern from those during the day. Tests over a 
3-day period confirmed an asymmetrical variation 
of cortisol levels over the two 12-h periods (Fig. 8) 
(57). 
These modelling techniques could be used to 
predict the concentration of circulating FP from 
cortisol measurements taken at a given time after 
FP dosing. In a similar way, serum cortisol levels 
can be predicted at intervals following FP dosing. 
Simulations show that following a single dose of 
FP, 500 ug, serum cortisol levels remain within the 
average distribution. Simulations can also predict 
the dose of FP that would produce a clinically 
significant cortisol suppression (defined as 70% 
suppression). The simulation predicted a result in 
normal volunteers of FP, 2.5 mg; suppression 
occurred during the day, with levels recovering to 
within the normal range at night. 
Although not validated for multi-dose use, the 
model parameters, when applied to a twice-daily 
regimen of FP described in the literature (42) pro- 
vided an accurate prediction of the levels of cortisol 
at steady state seen in the volunteers. The actual 
change was, however, exaggerated by the use of 
results over a 20-h period only, which leaves out the 
early morning ‘catch-up’. 
The results of these models are now being com- 
pared with historical control data from studies of 
FP in which cortisol measurements were taken. 
Although some inter-individual variation in cortisol 
levels occurs over the day, initial indications are 
that these are not sufficiently large to invalidate the 
model. Research has also shown that a similar 
relationship holds for asthma patients as for healthy 
volunteers. Therefore, much higher doses of FP 
will be needed before clinically significant cortisol 
suppression is seen in patients with asthma. These 
data also show the need to record both pharmaco- 
kinetics and cortisol levels; the two are closely 
related. Study designs which alter pharmaco- 
kinetics can give artificially high (or low) cortisol 
results. 
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Conclusion 
Preclinical studies have demonstrated that FP is a 
highly lipophilic molecule, a characteristic which 
results in rapid penetration into the cells and reten- 
tion in lung tissue. Fluticasone propionate has also 
been found to have high glucocorticoid-receptor 
selectivity with highly desirable ‘fast-on, slow-off 
receptor kinetics. The net effect is a FP-receptor 
half-life of 10 h, markedly greater than the receptor- 
drug half-lives of 7.5 and 5.1 h for beclomethasone- 
17-monopropionate (the active metabolite of BDP) 
and budesonide, respectively. 
These differences in biological properties appear to 
be predictive of differing clinical effects. Studies 
evaluating lung function, exacerbation rate and oral 
corticosteroid-sparing effect all suggest that FP has a 
dose-dependent clinical potency which is at least 
two-fold greater than BDP and budesonide. Studies 
have also indicated that this increased clinical 
potency does not result in increased systemic activity. 
This separation between efficacy and systemic 
potency is a combination of negligible oral bioavail- 
ability, slow absorption from the lungs into the 
plasma and metabolic profile. 
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